Abstract:Enteric fever is caused by the infection of Gram-negative bacteria, Salmonella enterica serovar Typhi and Salmonella enterica serovar Paratyphi (S. Paratyphi) A, B and C, through contaminated food and water. The disease almost exclusively affects the populations living in low- and middle-income countries, with the World Health Organization Southeast Asian Region (WHO SEAR) having the highest endemicity. Despite humans being the sole reservoir of infection and antibiotics and vaccines are made available, the disease was not taken up for elimination until recently due to several biological and technical reasons, including the lack of accurate and region-specific disease surveillance data in the real-time diagnostic inaccuracy of acute infections, difficulty in identifying the chronic asymptomatic carriers who are the major reservoirs of infection and the absence of a political will. However, there is now a renewed interest and effort to control the disease in the endemic areas with the help of better surveillance tools to monitor disease burden, wider availability of more accurate blood culture methods for diagnosis, and above all, cost-effective typhoid conjugate vaccines (TCVs) that can provide a high level of durable protection, particularly against the multidrug-resistant strains and to the age group most commonly affected by the disease. However, despite the commercial availability of a few TCVs, they are still in the development stage. Several questions need to be answered before they are taken up for routine immunization in countries like India. Furthermore, typhoid vaccines with a wider coverage, including additional efficacy against Salmonella Paratyphi A and B and preferably the non-typhoidal Salmonella (NTS) serovars, for which no vaccines are currently available would be more desirable. We have developed several subunit vaccine candidates containing the glycoconjugates of the surface polysaccharides of typhoidal and non-typhoidal Salmonellae and an intrinsic Salmonella protein that functions as both antigen and adjuvant. We also developed a novel mouse model of oral Salmonella Typhi infection to test the candidate vaccines, which demonstrated broad protective efficacy against Salmonella spp. through the induction of humoral and cell-mediated immunity as well as memory response.

Vaccine development for enteric bacterial pathogens: Where do we stand?

Progress and Hurdles in the Development of Vaccines Against Enterotoxigenicescherichia Coliin Humans

Progress in enteric vaccine development

Update on vaccines for enteric pathogens

Vaccines against gastroenteritis, current progress and challenges (Reprinted from Gut Microbes, vol 11, pg 1486-1517, 2020)

Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part I: Overview, vaccines for enteric viruses and Vibrio cholerae

Vaccines against gastroenteritis, current progress and challenges

Enteric infections and the vaccines to counter them: Future directions

A review of the current status of enteric vaccines

[Advances in new vaccines against human enterotoxigenic Escherichia coli--A review]

[Vaccination against diarrheal diseases and typhoid fever. Current status and prospects]

Current Progress in Developing Subunit Vaccines Against Enterotoxigenic Escherichia Coli-Associated Diarrhea

The Diversity of Escherichia coli Pathotypes and Vaccination Strategies against This Versatile Bacterial Pathogen

Enterotoxigenic Escherichia coli Infections

Future Vaccines Against Enteric Pathogens

Status of vaccine research and development for enterotoxigenic Escherichia coli

Typhoid & paratyphoid vaccine development in the laboratory: a review & in-country experience

Vaccines for the prevention of diarrhea due to cholera, shigella, ETEC and rotavirus

Recent advancement, immune responses, and mechanism of action of various vaccines against intracellular bacterial infections

IMMUNITY IN CHOLERA AND VACCINE DEVELOPMENT: PROBLEMS AND PROSPECTS

Vaccines and milk immunoglobulin concentrates for prevention of infectious diarrhea